Educational reference only. Not medical advice. Research compounds are not for human or veterinary use.

Peptides for PCOS and POTS: what the evidence shows

PCOS and POTS are two conditions where people often feel let down by standard care, so it is no surprise that peptides get promoted for both. The honest picture is very different for each. For PCOS, one family of peptide drugs, the GLP-1 medicines, has real but limited trial evidence. For POTS, the only peptides with human data are older prescription drugs, and the popular research peptides have none. Here is what the evidence actually shows. Both conditions need a clinician's care, and nothing here replaces that.

PCOS

What PCOS is

Polycystic ovary syndrome affects an estimated 10% to 13% of women of reproductive age, and the World Health Organization says up to 70% of those affected worldwide do not know they have it. It involves irregular or absent ovulation, higher androgen (male-type hormone) levels and often polycystic-looking ovaries on ultrasound. Insulin resistance is common, and PCOS raises the long-term risk of type 2 diabetes and obesity. That metabolic side is where peptide drugs come in.

GLP-1 drugs: the strongest evidence

GLP-1 receptor agonists such as liraglutide and semaglutide are peptide drugs that lower blood sugar, reduce appetite and cause weight loss. In PCOS they have been studied mainly for weight and insulin resistance:

  • Liraglutide: in a 32-week randomized trial of 82 women with PCOS and obesity, those on liraglutide lost 5.7% of body weight on average versus 1.4% on placebo. Free androgen levels improved, though total testosterone did not change significantly (Elkind-Hirsch et al., 2022).
  • Semaglutide: in a small study of 27 women with PCOS and obesity who had not lost weight with lifestyle changes alone, most lost at least 5% of their weight within three months, and many regained regular cycles. The study had no control group, and a third of participants reported nausea.
  • Pooled evidence: a 2025 network meta-analysis of 27 randomized trials with 1,642 participants found GLP-1 drugs reduced weight and waist size and improved insulin resistance, androgen measures and menstrual frequency in PCOS. Some of that evidence was rated very low certainty. A 2024 review for the international PCOS guideline called the published data on anti-obesity drugs in PCOS "very limited."
  • Tirzepatide: a 72-week randomized, placebo-controlled trial in 198 women with PCOS began in December 2025 and is still recruiting. A 2026 real-world analysis found women with PCOS lost about as much weight on tirzepatide as women without it. There is no completed randomized tirzepatide trial in PCOS yet.

What the guidelines say

The 2023 International Evidence-based Guideline for PCOS says anti-obesity medicines, including the GLP-1 drugs liraglutide and semaglutide, could be considered alongside lifestyle changes for adults with PCOS and higher weight. It also says clinicians should make sure effective contraception is in place when pregnancy is possible, and that these drugs should be used to improve fertility outcomes only in research settings. Metformin remains the long-standing first-line medicine for metabolic features of PCOS.

No GLP-1 drug is FDA-approved specifically for PCOS. When prescribed for PCOS, they are used for an approved purpose such as weight management or diabetes, or off label.

Pregnancy and birth control cautions

  • The Wegovy label advises stopping semaglutide at least two months before a planned pregnancy.
  • Tirzepatide can make birth-control pills less reliable, especially after starting and after each dose increase, so its label recommends a non-oral method or a backup method for those periods.
  • Weight loss can restore ovulation in PCOS, and there have been many anecdotal reports of unplanned pregnancies on these drugs. That is one more reason this decision belongs with a clinician.

Kisspeptin: a research tool, not a treatment

Kisspeptin is a natural peptide that switches on the reproductive hormone system. A 2019 meta-analysis found kisspeptin levels tend to be higher in women with PCOS. At Imperial College London, researchers used kisspeptin-54 to trigger egg maturation during IVF in 60 women at high risk of ovarian hyperstimulation syndrome, a dangerous IVF complication that is more common in PCOS. None developed moderate or severe hyperstimulation. Kisspeptin is still investigational and is not an approved fertility drug. See our kisspeptin brief.

What about BPC-157 and other research peptides?

We found no human studies or registered trials of BPC-157, TB-500, thymosin alpha-1 or similar research peptides in PCOS.

POTS

What POTS is

Postural orthostatic tachycardia syndrome means the heart rate climbs too much on standing: by at least 30 beats per minute within 10 minutes in adults, or 40 in teenagers, without a drop in blood pressure, along with symptoms such as lightheadedness, fatigue and brain fog lasting at least six months. It affects an estimated 0.2% to 1% of people, up to 3 million Americans. There is no FDA-approved drug for POTS.

POTS has drawn new attention since the pandemic. In a Swedish study of 467 people with long COVID who had not been hospitalized, 31% were diagnosed with POTS.

The peptides that have actually been studied

The only peptides with POTS data are older prescription drugs, studied in small trials:

  • Desmopressin, a synthetic version of the body's water-retaining hormone vasopressin. In a randomized crossover study of 30 people with POTS, a single dose lowered standing heart rate (about 102 versus 109 beats per minute on placebo) and improved symptoms. The main risk is low blood sodium (hyponatremia), especially because people with POTS are told to drink extra fluids, so specialists use it only occasionally and with blood tests.
  • Octreotide, a synthetic version of the hormone somatostatin, which narrows blood vessels in the gut and can reduce blood pooling. In a small open-label study, standing heart rate fell from about 106 to 93 beats per minute and standing time improved in the five patients who finished. It has been compared with midodrine in another small study.

Both are used off label, under specialist supervision.

A caution about GLP-1 drugs and POTS

GLP-1 drugs raise resting heart rate slightly, by about 1 to 4 beats per minute on average, and in Wegovy trials 26% of adults had a peak rise of 20 beats per minute or more, versus 16% on placebo. For most people that is minor. For someone whose main problem is a racing heart, it may not be. A 2025 case report described a woman whose well-controlled POTS returned after she started tirzepatide, with heart rates rising 20 to 30 beats per minute. One case does not prove cause, but it is worth discussing with a clinician before starting any GLP-1 drug if you have POTS.

Research peptides

We found no human studies or registered trials of BPC-157, TB-500, thymosin alpha-1 or other research peptides in POTS. Claims that they help POTS are not based on published evidence.

What standard care looks like

First-line care for POTS usually includes more fluids and salt, compression garments, gradual exercise reconditioning and stopping medicines that worsen symptoms. Medicines such as fludrocortisone, midodrine, propranolol, ivabradine and pyridostigmine are used off label. Evidence for each is limited: in a 2026 NIH trial in 181 adults with long-COVID POTS, ivabradine lowered heart rate but did not significantly improve symptoms.

The bottom line

  • PCOS: GLP-1 drugs have real trial evidence for weight and insulin resistance, and guidelines say they can be considered for adults with PCOS and higher weight, with contraception in place. They are not approved for PCOS itself, and fertility use is still a research question.
  • POTS: desmopressin and octreotide have small studies and real risks; GLP-1 drugs may make the heart rate problem worse in some people.
  • Research peptides have no human evidence for either condition.

Both conditions vary a lot from person to person. Work with a clinician who knows the condition, ideally a specialist.

Key references

This post is educational. It does not give dosing guidance and is not medical advice. If you have PCOS or POTS, work with a clinician on any treatment decision.

Educational content only

Peptide Knowledge is an educational reference. Nothing on this site is medical advice, a treatment recommendation or dosing guidance. Many compounds described here are not approved for human use and are sold for laboratory research only. Talk to a licensed clinician before starting, stopping or changing any medication or supplement.

All blog posts